Latest Breaking News On - Ipocine lpcn us53630x1046 - Page 1 : comparemela.com

LIPOCINE ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of liver cirrhosis SALT LAKE CITY, December 22, 2021 - Lipocine Inc. , a clinical-stage. | December 22, 2021

United statesHans vitzhumMorgan brownMahesh patelLipocine incSkeletal muscle indexChief executive officerOrphan drug designationHepatic encephalopathyLiver cirrhosisCompromised musclePrivate securities litigation reform actLipocine inc stock exchangePress releaseIpocine lpcn us53630x1046